Document:

<PAGE>

                                                                     Exhibit 4.1

                                                                         [STAMP]

                 AMENDMENT TO THE CERTIFICATE OF DESIGNATIONS,
                            PREFERENCES, AND RIGHTS
                                       of
                           SERIES A PREFERRED STOCK,
                         SERIES B PREFERRED STOCK, AND
                            SERIES C PREFERRED STOCK
                                       of
                               GLYCOGENESYS, INC.

          We, Bradley J. Carver and John W. Burns, the President and the
Secretary, respectively, of GlycoGenesys, Inc., a corporation organized and
existing under the laws of the State of Nevada (the "Corporation"), in
accordance with the provisions of Section 78.1955 of the Nevada Revised
Statutes, DO HEREBY CERTIFY:

          WHEREAS, on June 22, 2001, the Board of Directors of the Corporation
(the "Board of Directors") adopted a resolution creating three series of shares
of preferred stock designated as the "Series A Preferred Stock," the "Series B
Preferred Stock," and the "Series C Preferred Stock"; and

          WHEREAS, the Board of Directors and the holders of the Corporation's
Series A preferred stock, par value U.S. $0.01 per share ("Series A Preferred
Stock"), Series B preferred stock, par value U.S. $0.01 per share ("Series B
Preferred Stock") and Series C preferred stock, par value U.S. $0.01 per share
("Series C Preferred Stock") desire to amend certain powers, preferences and
other special rights of the Series A Preferred Stock, Series B Preferred Stock
and Series C Preferred Stock.

          NOW, THEREFORE, pursuant to the authority conferred upon the Board of
Directors by the Articles of Incorporation of the Corporation and by Section
78.1955 of the Nevada Revised Statutes, on April 15, 2002, the Board of
Directors adopted, and holders of a majority of the Corporation's Series A
Preferred Stock, Series B Preferred Stock and Series C Preferred Stock approved,
the following resolution, amending and restating the Certificate of
Designations, Preferences, and Rights of Series A Preferred Stock, Series B
Preferred Stock and Series C Preferred Stock of the Corporation:

     "RESOLVED, that pursuant to the authority vested in the Board of Directors
     (the "Board of Directors") of GlycoGenesys, Inc., a corporation organized
     and existing under the laws of the State of Nevada (the "Corporation"), by
     the Certificate of Incorporation of the Corporation (the "Certificate of
     Incorporation"), the Board of Directors does hereby amend and restate,
     effective as of July 9, 2001, the designations, powers, preferences, and
     relative participating, optional, or other special rights, and the
     qualifications, limitations, and restrictions of the

<PAGE>

     Corporation's Series A Preferred Stock, Series B Preferred Stock and Series
     C Preferred Stock, as follows (respectively, the "Series A Designation",
     the "Series B Designation", and the "Series C Designation"):

     1.     Section 3(a) of Article I of the Certificate of Designations shall
be amended and restated in its entirety to read as follows:

     "(a)   Liquidation Events. The occurrence of any of the following events
     shall be deemed a "Liquidation": (i) any liquidation, dissolution, or
     winding-up of the affairs of the Corporation; (ii) any consolidation or
     merger of the Corporation with or into any other corporation or other
     entity or person, or any other corporate organization in which the
     stockholders of the Corporation immediately prior to such consolidation,
     merger or reorganization, own less than 50% of the outstanding voting
     securities of the surviving or resulting entity immediately after such
     consolidation, merger or reorganization (a "Merger Event"); (iii) any
     transaction or series of related transactions approved by the Board of
     Directors of the Corporation in which securities of the Corporation
     representing 50% or more of the combined voting power of the Corporation's
     then outstanding voting securities are acquired by a person, entity or
     group of related persons or entities, excluding any consolidation or merger
     effected exclusively to change the domicile of the Corporation; or (iv) any
     sale, lease, exclusive license or other disposition of all or substantially
     all of the assets of the Corporation."

     2.     Section 3(b)(iii) of Article I of the Certificate of Designations
shall be amended and restated in its entirety to read as follows:

     "(iii) After the distributions described in clause (b)(i) above have been
     paid, subject to the rights of any other class or series of capital stock
     of the Corporation that may from time to time come into existence, in the
     event of a Liquidation described in clause (i) or clause (iv) of Section
     3(a) of this Article I, the remaining assets of the Corporation available
     for distribution to stockholders shall be distributed among the holders of
     Common Stock, the holders of the Series A Preferred Stock, and the holders
     of any other class or series of capital stock of the Corporation entitled
     to share in such distribution pro rata based on the number of shares of
     Common Stock held by each, assuming conversion of any other class or series
     of capital stock of the Corporation convertible into shares of Common
     Stock."

     3.     Section 6(a) of Article I of the Certificate of Designations shall
be amended and restated in its entirety to read as follows:

     "(a)   On July 10, 2007, if any shares of the Series A Preferred Stock
     shall be outstanding, the Corporation shall redeem all outstanding shares
     of the Series A Preferred Stock, at a redemption price per share equal to
     the aggregate Series A Liquidation Preference, either (i) to the extent the
     Corporation shall have funds legally available for such payment, in cash,
     or (ii) by the issuance of shares of Common Stock with an

                                        2

<PAGE>

     aggregate Fair Market Value (as defined below) equal to such redemption
     price, in each case, together with any accrued and unpaid dividends thereon
     to the date fixed for redemption. For the purposes of this Section 6, and
     Section 4(e)(i) of this Article I and Sections 4(e)(i) of Article II, the
     "Fair Market Value" of one share of Common Stock shall be determined by the
     Board of Directors in good faith and certified in a board resolution
     (taking into account the most recently of concurrently completed arm's
     length transaction between the Corporation and an unaffiliated third party
     the closing of which occurs within the six months preceding or on the date
     of such calculation, if any) and shall be reasonably agreed to by a
     majority of the holders of the Series A Preferred Stock or, as applicable,
     the Series B Preferred Stock; provided, that in the event the Corporation
     and a majority of holders of the Series A Preferred Stock or, as
     applicable, the Series B Preferred Stock do not agree on the Fair Market
     Value the parties shall jointly appoint an independent third party
     appraiser to determine the Fair Market Value pursuant to the procedure set
     forth in Section 3(d) of this Article I; provided further, that in the
     event the Common Stock is traded on a securities exchange, the Nasdaq
     National Market or the Nasdaq SmallCap Market, the Fair Market Value shall
     be deemed to be the average of the closing sale prices for the Common Stock
     over the 30-day trading period (or such shorter period for which closing
     sale prices are available if the Common Stock commenced trading during such
     period) ending three (3) trading days prior to, in the case of this Section
     6, the date of notice of exercise of redemption pursuant to this Section 6,
     in the case of Section 4(c)(i) of this Article I or, as applicable, Section
     4(e)(i) of Article I, the date of the sale of Additional Shares that
     results in an adjustment to the Series A Conversion Price pursuant to
     Section 4(e)(i) of this Article I or, as applicable, the Series B
     Conversion Price (as defined in Article II) pursuant to Section 4(e)(i) of
     Article II; provided further, that for the purpose of this Section 6 the
     Fair Market Value shall be deemed to be at least $0.50 per share (the
     "Share Floor Price"). The Share Floor Price shall be proportionately
     adjusted for any stock split, stock combination or similar event affecting
     the Common Stock."

     4.     Section 3(a)(iii) of Article II of the Certificate of Designations
shall be amended and restated in its entirety to read as follows:

     "(iii) After the distributions described in clause (a)(i) above have been
     paid, subject to the rights of any other class or series of capital stock
     of the Corporation that may from time to time come into existence, in the
     event of a Liquidation described in clause (i) or clause (iv) of Section
     3(a) of Article I, the remaining assets of the Corporation available for
     distribution to stockholders shall be distributed among the holders of
     Common Stock, the holders of the Series B Preferred Stock, and the holders
     of any other class or series of capital stock of the Corporation entitled
     to share in such distribution pro rata based on the number of shares of
     Common Stock held by each, assuming conversion of any other class or series
     of capital stock of the Corporation convertible into shares of Common
     Stock."

                                        3

<PAGE>

       5.  Section 3 of Article III of the Certificate of Designations shall be
amended and restated in its entirety to read as follows:

       "3. In the event of a Liquidation described in clause (i) or clause (iv)
       of Section 3(a) of Article I, whether voluntary or involuntary, the
       holders of Series C Preferred Stock shall have the right to receive, pari
       passu with the holders of the Common Stock and subject to the rights of
       the holders of any other senior class or series of capital stock of the
       Corporation, the assets of the Corporation in proportion to the number of
       shares of Common Stock held by each such holder (assuming, for such
       purposes, the holders of Series C Preferred Stock are deemed to hold that
       number of shares of Common Stock equal to the number of shares of Common
       Stock into which such shares of Series C Preferred Stock are then
       convertible)."

                            (signature page follows)

                                       4

<PAGE>

         IN WITNESS WHEREOF, said GlycoGenesys, Inc. has caused this Amendment
to the Certificate of Designations, Preferences and Rights of Series. A
Preferred Stock, Series B Preferred Stock and Series C Preferred Stock to be
signed by Bradley J. Carver, its President, and John W. Burns, its Secretary,
this 16/th/ day of April, 2002.

                                        GLYCOGENESYS, INC.

                                        By: /s/ Bradley J. Carver
                                            -------------------------
                                            Name:  Bradley J. Carver
                                            Title: President

                                        By: /s/ John W. Burns
                                            -------------------------
                                            Name:  John W. Burns
                                            Title: Secretary

State of Massachusetts
         -------------

County of  Suffolk
          ------------

         I. Richard Gallant a notary public, do hereby certify and attest that
the attached document is a true and exact copy of the Amended and Restated
Certificate of Designations. Preferences, and Rights of Series A Preferred
Stock, Series B Preferred Stock, and Series C Preferred Stock of the Company and
that on this 16/th/ day of April, 2002, personally appeared before me, Bradley
J. Carver and John W. Burns, who being by me first duly sworn, declared that
they are the President and Secretary of the Company, respectively, that they
signed the foregoing document as President and Secretary of the Company, and
that the statements therein contained are true.

                                        /s/ Richard A. Gallant
                                        -----------------------------
                                        Notary Public

                               RICHARD A. GALLANT
                                  Notary Public
                         Commonwealth of Massachusetts
                             My Commission Expires
My commission expires          November 21, 2002                        [STAMP]
                               -----------------<PAGE>

                                                                    Exhibit 10.1

GlycoGenesys, Inc.                                                April 15, 2002
Master Agreement for Consulting Services                                  Page 1

================================================================================

                              CONSULTING AGREEMENT

                                 by and between

                               GlycoGenesys, Inc.

                                       and

                       BEARDSWORTH CONSULTING GROUP, INC.

===============================================================================

               [LETTERHEAD OF BEARDSWORTH CONSULTING GROUP, INC.]

<PAGE>

GlycoGenesys, Inc.                                                April 15, 2002
Master Agreement for Consulting Services                                  Page 2

                              CONSULTING AGREEMENT

         This Agreement is by and between Beardsworth Consulting Group, Inc. a
New Jersey corporation, having an address at 70 Church Street, Suite 200,
Flemington, NJ 08822, (hereinafter called "BCGI(R)"); and GlycoGenesys, Inc.
(hereinafter called "Client"); having an address at, 31 Saint James Avenue,
Boston, MA 02116.

                               W I T N E S S E T H

         WHEREAS, BCGI represents that it is under no obligation to any third
party that would interfere with the rendering to Client professional services as
hereinafter defined; and

         WHEREAS, Client is desirous of engaging BCGI's professional services;
and

         WHEREAS, BCGI desires to render professional services to Client in the
performance of agreed-upon tasks or services;

         NOW, THEREFORE, in consideration of the premises and of the mutual
promises and covenants herein contained, the parties hereto agree as follows:

         1. Prior to commencing any work hereunder, the definitions of any
specific task or project to be performed shall be agreed upon by the parties,
and attached to and made a part of this Agreement as an Attachment.

         2. BCGI shall use its best efforts to provide consulting services in
accordance with the terms of accepted offers, to keep Client advised of the
progress of the work, to permit any representative duly authorized in writing by
Client to inspect, from time to time, such results of said consulting services
as are susceptible of inspection, to provide Client with such reports,
specifications, drawings, models, and the like, as are appropriate to the nature
of the services to be contemplated by any accepted offer and to keep records of
hours worked and costs of materials used, as well as other reasonable
out-of-pocket expenses, which such records Client's duly authorized
representative may examine upon reasonable notice to BCGI.

         3. Any confidential information acquired by BCGI, its employees,
subcontractors and affiliates from Client concerning existing or contemplated
machines, products, processes, techniques, or know-how, or any information or
data developed pursuant to the performance of the consulting services
contemplated by any accepted offer made by Client shall not be disclosed by BCGI
to others or used for BCGI's own benefit without the prior written consent of
Client. This obligation of confidentiality shall not apply to:

         a. information which, at the time of disclosure to BCGI by Client is
            published, known publicly, or is otherwise in the public domain;
         b. information which, after it is disclosed to BCGI by Client is
            published, becomes known publicly, or otherwise becomes part of the
            public domain, through no fault of BCGI;

<PAGE>

GlycoGenesys, Inc.                                                April 15, 2002
Master Agreement for Consulting Services                                  Page 3

         c. information disclosed to BCGI by Client which prior to the time of
            disclosure is known to BCGI, as evidenced by written records; and
         d. information which has been or hereafter is disclosed to BCGI in good
            faith by a third party who was not, and is not, under any obligation
            of confidence or secrecy to Client at the time said third party
            discloses to BCGI.
         e. information, which is required by law, regulation, or legal process
            to be disclosed.

         It is understood that the obligations of confidentiality and nonuse set
forth herein shall survive the termination of this Agreement. In addition to the
confidentiality provisions set forth herein, BCGI and Client shall execute the
Client's confidentiality agreement, subject to BCGI's approval.

         4. Any copyrightable work created by BCGI in connection with or during
the performance of services pursuant to this Agreement by BCGI shall be
considered a work made for hire, whether published or unpublished, and all
rights therein shall be the property of Client as employer, author and owner of
the copyright in such work. BCGI, without charge to Client other than reasonable
payment for time involved in the event the services contemplated by any accepted
offer shall have terminated, but at Client's expense, shall duly execute,
acknowledge, and deliver to Client all such further papers, including
assignments and applications for copyright registration or renewal, as may be
necessary to enable Client to publish or protect said works by copyright or
otherwise in any and all countries and to vest title to said works in Client, or
its nominees, their successors or assigns, and shall render all such assistance
as Client may require in any proceeding or litigation involving the rights in
said works. BCGI shall promptly notify Client of any copyrightable work
contemplated herein.

         5. Any inventions, improvements, or ideas made or conceived in
connection with or during the performance of services by BCGI pursuant to this
Agreement, and directly related to such services, shall be the property of
Client. BCGI shall promptly notify Client of any such inventions, improvements
or ideas. BCGI, without charge to Client other than reasonable payment for time
involved in the event the services contemplated by any accepted offer shall have
terminated, but at Client's expense shall execute, acknowledge, and deliver to
Client all such further papers, including applications for patents, as may be
necessary to enable Client to publish or protect said inventions, improvements,
and ideas by parent or otherwise in any and all countries and to vest title to
said patents, inventions, improvements, and ideas in Client or its nominees,
their successors or assigns, and shall render all such assistance as Client may
require in any Patent Office proceeding or litigation involving said inventions,
improvements, or ideas.

         6. Client hereby recognizes and understands that BCGI presently and may
from time to time in the future contract with other consultants to perform
certain services pursuant to this Agreement. Each subcontractor has executed a
written agreement with BCGI which incorporates provisions of the character and
scope of Paragraphs 3 through 5 of this Agreement which inure to the benefit of
BCGI and its clients and customers. BCGI hereby covenants and agrees that all of
its employees, consultants, and principals shall, previous to performing
services pursuant to this Agreement, execute a written agreement with BCGI which
incorporates provisions of the character and scope of Paragraphs 3 through 5 of
this Agreement which inure to the benefit of BCGI and its clients and customers.
Client may waive this requirement with

<PAGE>

GlycoGenesys, Inc.                                                April 15, 2002
Master Agreement for Consulting Services                                  Page 4

respect to nonprofessional personnel regularly employed at BCGI's place of
business and whose work is performed strictly in accordance with BCGI's
directions.

         7.  Client reserves the right forthwith to direct, by written notice,
BCGI to discontinue with [***] written notice the work upon which BCGI shall
have been engaged for Client, in which event Client shall be obligated to pay
BCGI for work done by BCGI and for cost of materials for which BCGI has become
obligated in connection with the contemplated services. BCGI shall commit to use
its best efforts to minimize costs after which such notice is given. During the
[***] period from written discontinuation notice to project transfer, BCGI will
provide transitional support as required.

         8.  Client hereby offers to engage and BCGI accepts engagement by
Client of BCGI's professional services as follows: to render consulting services
to personnel of Client relating to clinical research, regulatory (FDA
submissions), technical writing, and product development matters associated with
Client products or potential products in accordance with the terms and
provisions of this Agreement.

         9.  In consideration of BCGI's acceptance of this Consulting Agreement
and of its performance of the professional services as specifically set forth in
Paragraph 8 hereof, Client shall retain BCGI for the following rates unless
alternate rates are otherwise specified in an Attachment to this master
agreement:

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------
               Category                 Hourly                        Category                    Hourly
                                         Rate                                                      Rate
------------------------------------------------------------------------------------------------------------
<S>                                     <C>                                                       <C>
Administrative Staff                     [***]    Project Manager                                  [***]
------------------------------------------------------------------------------------------------------------
Data Entry Staff                         [***]    Medical Writer                                   [***]
------------------------------------------------------------------------------------------------------------
Clinical Data Coordinator                [***]    Quality Control Document Reviewer                [***]
------------------------------------------------------------------------------------------------------------
CRF Designer                             [***]    Quality Assurance Site Auditor                   [***]
------------------------------------------------------------------------------------------------------------
Clinical Document Reviewer               [***]    Specialty Committee Members (DMC)                [***]
------------------------------------------------------------------------------------------------------------
Data Entry Manager                       [***]    Regulatory Affairs Specialist                    [***]
------------------------------------------------------------------------------------------------------------
SAS Programmer                           [***]    Medical Director (M.D.)                          [***]
------------------------------------------------------------------------------------------------------------
Director of Systems Development          [***]    Vice President, Business Development             [***]
------------------------------------------------------------------------------------------------------------
Biostatistician (Ph.D.)                  [***]    Vice President, Clinical Services                [***]
------------------------------------------------------------------------------------------------------------
Clinical Research Associate              [***]    Donna E. Beardsworth                             [***]
------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------
</TABLE>

         10. Client agrees to reimburse BCGI for reasonable travel and
out-of-pocket expenses incurred by BCGI while performing the consulting services
for Client. Such expenses shall include but not be limited to airfare,
accommodations, meals, rental cars, courier expenses, telephone and fax and
other reasonable travel expenses. Specifics of the agreed upon travel policy are
put forth in Exhibit 1. Travel and out-of-pocket expenses will be invoiced
monthly by BCGI with copies of all receipts for individual expenses greater than
five dollars ($5.00). Payments shall be due to BCGI upon receipt of invoice, net
30 days.

***    Portions of this page have been omitted pursuant to a request for
       Confidential Treatment and filed separately with the Commission.

<PAGE>

GlycoGenesys, Inc.                                                April 15, 2002
Master Agreement for Consulting Services                                  Page 5

         11. Client shall have no obligation whatsoever to compensate BCGI for
services rendered hereunder beyond the sums referred to in Paragraphs 7, 9 and
10 herein.

         12. The role of BCGI will be outlined in each project specific
'transfer of obligation' appendix to this agreement. Otherwise, BCGI is not
acting as a "contract research organization" or a "sponsor" as defined in Title
21 of the Code of Federal Regulations of the Food and Drug Administration of the
United States of America. Client retains full responsibility for the content of
documents and regulatory submissions, for interpretation of data therein and for
the timing, preparation and processing of required regulatory submissions.

         13. BCGI represents that it is free to enter into this agreement and
agrees not to knowingly disclose to Client any information with respect to which
it is under any actual or implied duty to any third party to keep confidential.
Client shall be free to use all information conveyed to it by BCGI, with the
exception of the names, addresses, and compensation rates of BCGI subcontractors
and employees which are to remain confidential, whether before or after the
execution of this Agreement, without any further obligation to BCGI other than
as outlined herein.

         14. BCGI agrees not to originate any publicity, news release or other
public announcement, written or oral, whether to the public, press or otherwise,
relating to this Agreement, to any amendment hereto, or to the performance and
any results or information obtained hereunder, without Client's prior written
consent. BCGI may acknowledge that it is a consultant to Client. BCGI shall be
free to make any disclosure which, in the opinion of legal counsel, it is
required by law to make, but shall give Client an opportunity to review the form
of such disclosure in advance of its release.

         15. BCGI shall not act as an agent for Client and shall not have the
authority to bind Client in any dealings with third parties.

         16. Consulting services hereunder may be performed at BCGI's office,
Client's offices or other locations as mutually agreed upon. Consulting at
Client or locations other than BCGI's office shall require payment of travel
costs to BCGI.

         17. BCGI warrants and represents that the services provided under this
Agreement will be carried out in accordance with the standard of care
customarily observed with regard to such services in BCGI's profession.

         18. Client understands that BCGI now has and may in the future enter
into consulting relationships with other companies, and affiliates of Client.

         19. This Agreement shall be interpreted in accordance with the laws of
the state of the suing party.

         20. This Agreement shall commence on the date of execution and shall
continue until terminated as hereinafter provided by either party.

<PAGE>

GlycoGenesys, Inc.                                                April 15, 2002
Master Agreement for Consulting Services                                  Page 6

         21. Client agrees that it shall defend, indemnify, and hold BCGI, its
employees, and consultants, harmless from any loss, damage, or expense
(including reasonable attorney's fees and costs) arising out of any and all
claims, actions, suits, governmental or administrative proceedings relating to
the development, manufacture, or sale of Client products for which BCGI has
written or given advice. BCGI agrees to indemnify Client and hold Client
harmless for all claims, demands, and liabilities, to which Client is subjected
by reason of any breach by BCGI of the terms of this Agreement or by any action
taken or not taken by BCGI unless such action or inaction was at the specific
request of Client.

         22. Client, during the term of this Agreement and for [***] thereafter,
shall not, without the prior written consent of BCGI, directly or indirectly
solicit for employment or contract, attempt to employ or contract with or assist
any other entity in employing, contracting with or soliciting for employment or
contract any employee, subcontractor or executive who is at that time
employed/contracted by BCGI or who had been employed/contracted by BCGI within
the prior [***] period.

         23. This agreement shall supersede any and all prior agreements and
understandings between the parties respecting the subject matter hereof. No
verbal representations or statements made by any representative of BCGI or
Client not stated herein shall be of any force or effect. The provisions of this
Agreement for Consulting Services constitute the entire agreement between the
parties and their respective principals. No modification or amendment to this
agreement shall be binding unless agreed upon in writing and signed by the
parties. Failure of either party to enforce rights under this agreement shall
not constitute a waiver of such rights.

         24. BCGI hereby certifies that neither BCGI or any person employed by
BCGI is under or has been under investigation by the U.S. Food and Drug
Administration ("FDA") or has been debarred under Section 306(a) or (b) of the
Federal Food, Drug, and Cosmetic Act or pursuant to Generic Drug Enforcement Act
of 1992 or has a disqualification hearing pending or has been disqualified by
the FDA pursuant 21.C.F.R. Section 312.70, and no debarred person will in the
future be employed by BCGI in connection with any work to be performed by or on
behalf of Client which may later become part of any application for approval of
a drug or biologic FDA. If at any time after execution of this Agreement, BCGI
becomes aware (i) that it or any person employed by it is in the process of
being debarred, BCGI hereby certifies that it will notify Client immediately
upon its become aware of such debarment or process.

         25. BCGI agrees that it will, to the best of its ability (i) ensure
that investigators understand that written informed consent must be obtained
from all participating subjects prior to enrollment in the studies in accordance
with the requirements specified with the Code of Federal Regulations, the ICH
guidelines and all other Applicable Laws, that they must give a signed copy of
the informed consent to each subject and they must keep a copy in the subject's
files, and report and attempt to correct deficiencies in such practices, (ii)
ensure that investigators understand and comply with FDA guidelines for the
conduct of research, (iii) ensure that there will be acceptable facilities for
conduct of any study and immediately report and attempt to correct deficiencies,
(iv) ensure that investigators understand their obligation to conduct all
studies in compliance with the Protocol's requirements and to report and attempt
to correct deficiencies, (v) work with investigators to ensure that the rights,
welfare and safety of the

<PAGE>

GlycoGenesys, Inc.                                                April 15, 2002
Master Agreement for Consulting Services                                  Page 7

subjects are protected, and (vi) otherwise comply with any applicable law, rule
regulation, order, decision or decree including, without limitation, the Food
Drug & Cosmetic Act, as amended, and the rules and regulations thereunder and
the Health Insurance Portability and Accountability Act, as may be amended, and
the rules and regulations thereunder (HIPPA) (collectively, the "Applicable
Laws").

         26. Each of the parties hereto hereby warrant and represent that they
have power and authority to execute this Agreement and that this Agreement is
being executed by its duly authorized signatories. BCGI further represents and
warrants that it is under no obligation which conflicts with its duties
contemplated hereunder and agrees not to undertake any project which conflicts
with this Agreement and the duties contemplated hereunder.

         27. All equipment, materials, documents, data, information and
suggestions of every kind and description supplied to BCGI directly or
indirectly by Client or prepared or developed by BCGI pursuant to this Agreement
(except for BCGI's procedural manuals, personnel data, and computer software
developed by BCGI), or resulting from the services provided hereunder shall be
the sole and exclusive property of Client and shall be treated as Confidential
Information; provided that BCGI may retain copies of such materials as required
by Applicable Laws. Client shall have the right to make whatever use it deems
desirable of any such materials, documents, data and information.

         28. The protocols are incorporated by reference to this agreement, as
amended from time to time by consent of both parties.

         29. BCGI will use its best efforts to minimize the amount of turnover
of key personnel on the project. Changes of key personnel or director level
personnel will not be done without prior notification to Client.

         30. See Rider 1 Regarding Insurance Coverage.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the day and year signed below.

GLYCOGENESYS, INC.                        BEARDSWORTH CONSULTING GROUP,
                                          INC.

By: /s/ Chris Szuskiewicz                 By: /s/ Donna E. Beardsworth
    ------------------------------------      ----------------------------------
    Chris Szuskiewicz,                    Donna E. Beardsworth, President & CEO
    Sr. VP of Operations & Development

Date: 16 April 2002                       Date: 16 April 2002
      ----------------------------------        --------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]